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Abstract
The 5’ region of BRCA1 contains multiple regulatory sequences flanking the two alternative promoters α and
β and two alternative, non-coding exons, 1a and 1b. Aberrations within the 5’ region BRCA1 (encompassing
two alternative promoters α and β and exons 1a and 1b) may be associated with an increased risk of breast
and ovarian cancer. In this study we screened 150 patients for polymorphism and mutations in this region of
BRCA1. All probands came from familial breast and/or ovarian cancer that had been found to be mutation-
negative in a previous search for founder mutations in BRCA1 (185delAG, C61G, 4153delA, 5382insC) or
BRCA2 (6174delT, 9631delC). In our study we found several sequence alterations within the non-coding region
of BRCA1 by using direct DNA sequencing and allele-specific PCR amplification. Three families with a polymorphic
deletion in BRCA1 exon 1b (2223delAAAAA, Acc. U37574) were found. Moreover, two linked nucleotide
substitutions (2642A>T, 2743T>C, Acc. U37574)  in BRCA1 intron 1 were detected in 16 patients. In order
to assess the functional significance of these two sequence variants, we constructed a reporter vector encoding
firefly luciferase under the transcriptional and translational control of wild type and altered BRCA1 promoter
region. The reporter assay was performed using a lung cancer cell line (NCI-H1299) and a breast cancer cell
line (MCF7). We have demonstrated that the analysed sequence variants have no functional significance in our
experimental system. However, we have found that the BRCA1 promoter has lower relative activity in the breast
cancer cell line compared with the lung cancer cell line. Based on the results of our functional experiments we
conclude that the polymorphic deletion 2223delAAAAA and two linked substitutions 2642A>T and 2743T>C
do not significantly alter BRCA1 expression and are probably not disease-causing mutations. 
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Introduction
The human BRCA1 gene is under the transcriptional
control of two different promoters, α and β that drive
the transcription of exon 1a and 1b, respectively [22].
At the RNA level each of the alternative first exons is
linked by splicing with exon 2 [21]. However, the
translational initiation site is the same for the two mRNA
variants and is located in exon 2 [11]. The BRCA1
5`UTR region coded by exon 1b contains three
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additional ATG codons upstream of the major
translation initiation site [21]. The promoter α is bi-
directional and shared with the NBR2 gene [4, 21].
BRCA1 contains multiple transcription factor binding
sites identified in 5` flanking regions of exon 1a and
exon 1b [17, 18]. The different transcripts of the BRCA1
gene are present at different levels in various normal
and tumour tissues and may have distinct biological
functions [21]. Expression of transcripts α and β of the
BRCA1 gene may be co-regulated by use of a dual
promoter system. Moreover, the two mRNAs may differ
in their stability or translational efficiency [21]. 
Germline mutations within the BRCA1 gene are
responsible for familial cancer and reduced expression
of the BRCA1 gene is frequently observed in sporadic
breast [12, 16, 20] and ovarian tumours [23]. Various
mechanisms such as methylation of the CpG islands
within the promoter region [2, 6, 10, 13], allelic
deletion of the BRCA1 locus and sequence alterations
identified outside the BRCA1 coding region, especially
within the positive regulatory region (PRR) of the BRCA1
promoter, can modulate the level of BRCA1 expression
[17, 19]. There are also other mechanisms responsible
for breast and ovarian cancer pathogenesis [5, 15].
Expression patterns of BRCA1 mRNAs and differences
in their translatability [14] and disruption of the DNA-
protein complexes [18] may also contribute to
breast/ovarian cancer susceptibility.
Our aim was to investigate the functional effect of
sequence alterations within the BRCA1 promoter/5’UTR
region using luciferase reporter gene assay.
Material and methods
Patients
One hundred and fifty patients from families resident
in Upper Silesia, Poland, were screened for deletions in
the BRCA1 promoter/5’UTR region using genomic DNA
extracted from peripheral blood lymphocytes using the
phenol-chloroform method [7]. Each patient was selected
after clinical genetic counselling in which they completed
a detailed questionnaire, including family history, after
signing an informed consent document. Each person
selected for the study was diagnosed with breast and/or
ovarian cancer and had a positive family history of breast
and/or ovarian cancer. 
Screening for new sequence variants within BRCA1
promoter/5’UTR
Eighty-seven patients diagnosed with breast and/or
ovarian cancer were selected for BRCA1
promoter/5’UTR (GenBank accession no. U37574)
screening by direct DNA sequencing. All patients were
mutation-negative for founder mutations in the BRCA1
gene (185delAG, 300T/G, 4153delA, 5382insC) and
in the BRCA2 gene (6174delT, 9631delC) using ASA-
PCR and RFLP PCRs analyses [8, 9]. 
PCR amplification was performed using the following
primers (forward/reverse, 5’→3’): fragment 1
G A C G C T T G G C T C T T T C T G T
/TCTGGATCCTCCTCAAGCAC, fragment 2
G A G T G G A T T T C C G A A G C T G A /
TCTGGACCTCCTCAAGCAC, fragment 3
G A T G G G A C C T T G T G G A A G A A /
CGCGAAGAGCAGATAAATCC. All reactions were
performed in 15 µl containing 1 µl 50-150 ng DNA,
1xPCR buffer II (50 mM KCl, 10 mM Tris-HCl pH 8.3),
1.5 mM MgCl, 50 pmol each primer and 1U of
AmpliTaq DNA Polymerase (Applied Biosystem). The
PCR cycling conditions were: fragment 1, 94°C for 30s,
64°C for 30s, 72°C for 30s; fragment 2, 94°C for 30s,
59°C for 30s, 72°C for 30s; fragment 3, 94°C for 30s,
58°C for 30s, 72°C for 30s. An initial denaturation for
5 min. at 95°C and a final extension at 72°C for 7 min.
were also included in each PCR reaction. All reactions
were carried out for 35 cycles on a GeneAmpTM PCR
System 2400 (Applied Biosystem) thermal cycler. PCR
products were separated in a 2% agarose gel, 1xTBE,
stained with ethidium bromide and analysed using Scion
Image Beta 4.02 Win Software (Scion Corporation,
USA). Amplified products were purified before
sequencing with exonuclease I and shrimp alkaline
phosphatase according to the manufacturer’s protocol
(Amersham Life Science). Both strands were sequenced
using the following primers 5’→3’: fragment 1 (forward)
GACGCTTGGCTCTTTCTGTC, fragment 2 (forward)
GTAAGGCGTTGTGAACCCTG and fragment 3
(forward) GGAGACAGGATTTTGTGGGA, fragment 1
(reverse) CAGCCTCCTGAGTAGCTGGA fragment 2
(reverse) TCTGGATCCTCCTCAAGCAC fragment 3
(reverse) CGCGAAGAGCAGATAAATCC. Samples were
sequenced with BigDye Terminator Cycle Sequencing
Kit v3.1 (Applied Biosystem) and analysed with the ABI
Prism 377 DNA automated sequencer (Applied
Biosystem). 
Allele-specific PCR amplification was used to
estimate the frequency of the polymorphic deletion
2223delAAAAA in an additional sixty-three patients of
breast/ovarian cancer patients fulfilling the above
criteria. The following primers were used:
(5’→3’)TTTAAAAACGTCGGCTGGTC (forward),
TCCCACAAAATCCTGTCTCC (reverse) and
CAGCCGGTGTGTTTTGTTTT (reverse) with ‘touch-
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down’ PCR: denaturation at 95°C for 5 min. followed
by 10 cycles of 94°C 20s, 65°C 25s (at this point
temperature decreased 0.7°C per cycle), 72°C 30s
and followed by 30 cycles at 94°C 20s, 58°C 25s,
72°C 30s ending with a final extension of 72°C for 7
min. and a quick chill to 4°C. PCR reactions were
performed in 15 µl reactions containing 1 µl 50-150
ng DNA, 1xPCR buffer II (50 mM KCl, 10 mM Tris-HCl
pH 8.3), 1.5 mM MgCl, 50 pmol each primer and 1U
of AmpliTaq DNA Polymerase (Applied Biosystem). The
PCR product was amplified using a Mastercycler ep®
gradient S (Eppendorf) thermal cycler. The amplified
products were separated in 2% agarose gel. The
expected size of the PCR fragment containing a
polymorphic deletion within exon 1b was 261 bp.
Functional analyses of region BRCA1promoter/5’UTR
Plasmids. The 1.5 kb DNA region, encompassing
minimal BRCA1 promoter (promoter α), alternative
promoter (β), exons 1a, 1b and intron 1, in wild type and
in polymorphic forms, was amplified using the primers
5’→3’: TTTTGCTAGCCTTTATGGCAAACTCAGGTAG
and TTTTAAGCTTTCTGTTCCAATGAACTTTAAC. The
downstream and upstream primers were designed to
include NheI and HindIII sites, respectively (underlined).
The amplified products were digested with NheI and
HindIII and ligated into pGL3-Basic reporter vector
(Promega) digested with NheI and HindIII. The pGL3-
BRCA1-prom plasmids contain the firefly luciferase gene
(luc) under the transcriptional and translational control
of either the wild type or polymorphic BRCA1
promoter/5’UTR region (Figure 2). The identity of BRCA1
promoter constructs was confirmed by sequencing. The
inserts’ nucleotide sequences were compared with the
sequence U37574 from GeneBank. 
Cell culture, transfection and luciferase assay.
Functional analysis of the BRCA1 promoter/5’UTR
region was carried out in human non-small cell lung
cancer cell line NCI-H1299 and breast cancer cell line
MCF7 (obtained from ATCC). Cells were cultured in
DMEM or RPMI-1640 medium (respectively)
supplemented with 10% foetal calf serum and kept at
37°C and 5% CO2. Cell cultures were plated in 12-
well culture dishes at 24 hours prior to transfection. At
40% confluence, lung cancer NCI-H1299 and breast
cancer MCF7 cells were transfected with 0.5 µg DNA
of wild type or polymorphic reporter vectors using
FuGene6 (Roche) transfection reagent according to the
manufacturer’s instructions. pRL-TK reporter vector
coding for Renilla luciferase (Promega) was co-
transfected with pGL3-BRCA1-prom plasmids and
served as an internal control. The cells were incubated
with FuGene6-DNA for 24 hours. Subsequently the
cells were washed in phosphatate buffered saline, lysed
in 250 µl 1x Passive Lysis Buffer and 20 µl of the cell
lysates were assayed using the Dual-Luciferase Reporter
Assay System (Promega). Firefly luciferase activity was
divided by Renilla luciferase activity, which yielded
normalized firefly luciferase activity. This normalization
helps to minimize the confounding influence of
differences in cell number, transfection efficiency, etc.
Each pGL3-BRCA1-prom plasmid version was
Fig. 1. Schematic representation of the 5’ region of the BRCA1 gene
and location of sequence alterations found in this gene fragment –
1a and 1b represent two alternative first exons, 2 represents the
exon 2 with the translation start site
Fig. 2. The pGL3 - BRCA1 – prom plasmid map. The localization
of sequence alterations and the recognition sequences of the
restriction enzymes used for the cloning are shown. The thick arrow
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transfected to the three wells of the 12-well plate. The
mean and standard deviation from three luciferase
measurements were calculated and the statistical
significance of the differences were estimated using
the t-test.
Results and discussion
One hundred and fifty patients with breast and/or
ovarian cancer from Upper Silesia in Poland were
screened for sequence alterations in the 5’ region of
BRCA1. 
The polymorphic deletion 2223delAAAAA
(according to the GeneBank Acc. U37574) within
BRCA1 exon 1b was detected in three families (2%).
Two linked nucleotide sequence alterations within the
BRCA1 intron 1 2642A>T, 2743T>C (Acc. U37574)
were also detected in 16 patients (18.4%) (Figure 1). 
The functional impact of the most frequent sequence
variants within the 5’ region of BRCA1 was analysed by
the Dual-Luciferase Reporter Assay System (Promega)
in the lung cancer cell line (NCI-H1299) and breast
cancer cell line (MCF-7). Normalized firefly luciferase
activity was significantly lower in the MCF7 cell line
compared with the NCI-H1299 cell line (Figure 3).
All tested variants of the BRCA1 promoter/5`UTR
induced expression of the reporter gene at levels very
similar to the wild-type sequence in NCI-H1299 cell line
(2.15±0.32 and 2.02±0.27 versus 1.84±0.123;
P=0.19, t-test; Figure 3). The polymorphic sequences
slightly reduced expression of reporter luc gene compared
with wild-type BRCA1 promoter/5`UTR in MCF7 cell line
(0.51±0.024 and 0.55±0.012 versus 0.6±0.07);
however, the differences were not significant (P= 0.089,
P=0.263, t-test, respectively; Figure 3). The evidence
from this study suggests that the first polymorphism under
investigation could only slightly modulate the levels of
expression of the BRCA1 gene while the second
polymorphism (deletion of 5 nucleotides) did not
demonstrate any change in functional activity in the
experimental system used in this study. 
The 5’ region of BRCA1 contains multiple functional
domains which may regulate translation, transcription
and alternative splicing of BRCA1 [21, 22]. In this study
we analysed the BRCA1 5` region and detected several
sequence alterations. We cloned the region of interest
of the BRCA1 gene into the reporter plasmid in order
to find out if the sequence alterations modulate the
expression of the reporter gene. The deletion of five
adenines is a major sequence change. It is located in
exon 1b, which is an alternative exon present in the
mRNA mostly in cancer cells [21, 14]. It may change
the secondary structure of the 5’UTR of the alternative
mRNA, influencing translation efficiency. However, we
did not detect its influence on the reporter gene in
either of the two cancer cell lines that we used for the
assay. The two linked substitutions are located at the
3’ end of intron 1. In principle, they may modulate the
efficiency or accuracy of RNA splicing. However, in the
case of these linked sequence changes, we observed
no influence on reporter gene expression. Therefore,
we conclude that the sequence alterations have no
major functional impact on BRCA1 expression.
However, we cannot rule out the possibility that they
change regulation of BRCA1 expression in normal cells
or when present in their proper chromatin environment. 
Interestingly, we noticed that the activity of the reporter
gene controlled by BRCA1 promoter is significantly lower
in the MCF7 breast cancer cell line compared with the
lung cancer cell line (Fig. 3). Normalized firefly luciferase
activity can be regarded as a ratio of experimental
promoter activity (BRCA1 in this case) to the control
promoter activity (thymidine kinase gene promoter from
herpes simplex virus). This ratio is significantly lower in
MCF7 cells. This is consistent with the observation of
decreased BRCA1 protein level in breast cancer cell lines
and primary breast carcinomas associated with the
increased expression of negative regulators of BRCA1
promoter [1]. Methylation of the BRCA1 promoter region
also decreases the expression level of the protein [3], but
this mechanisms is found in a small number of BRCA1
















NFLA – normalized firefly luciferase activity
SUB – BRCA1 fragment with two linked nucleotide substitutions: 2642A>T,
2743T>C
DEL – BRCA1 fragment with deletion: 2223delAAAAA
Fig. 3. The normalized activity of the reporter gene (luc) under
transcriptional and translational control of the wild-type and
polymorphic forms BRCA1 promoter/5’UTR region in NCI-H1299
(grey) and MCF7 (dark grey) cell lines
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